|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intestinal microbiota in pathophysiology and management of irritable bowel syndrome显示文摘Irritable bowel syndrome(IBS) is a functional bowel disorder without any structural or metabolic abnormalities that sufficiently explain the symptoms, which include abdominal pain and discomfort, and bowel habit changes such as diarrhea and constipation. Its pathogenesis is multifactorial: visceral hypersensitivity, dysmotility, psychosocial factors, genetic or environmental factors, dysregulation of the brain-gut axis, and altered intestinal microbiota have all been proposed as possible causes. The human intestinal microbiota are composed of more than 1000 different bacterial species and 1014 cells, and are essential for the development, function, and homeostasis of the intestine, and for individual health. The putative mechanisms that explain the role of microbiota in the development of IBS include altered composition or metabolic activity of the microbiota, mucosal immune activation and inflammation, increased intestinal permeability and impaired mucosal barrier function, sensory-motor disturbances provoked by the microbiota, and a disturbed gut-microbiota-brain axis. Therefore, modulation of the intestinal microbiota through dietary changes, and use of antibiotics, probiotics, and anti-inflammatory agents has been suggested as strategies for managing IBS symptoms. This review summarizes and discusses the accumulating evidence that intestinal microbiota play a role in the pathophysiology and management of IBS. | Kang Nyeong Lee Oh Young Lee | 2014 | World Journal of Gastroenterology2014，20，27： | 35 |
| 2 | Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea显示文摘 | Won Sohn Oh Young Lee Sang Pyo Lee Kang Nyeong Lee Dae Won Jun Hang Lak Lee Byung Chul Yoon Ho Soon Choi Jongmin Sim Ki-Seok Jang | 2013 | Scandinavian Journal of Gastroenterology2013，，1： | 1 |
| 3 | Endoscopic histologic diagnosis of gastric GI submucosal tumors via the endoscopic submucosal dissection technique显示文摘 | Hang Lak Lee Oh Wan Kwon Kang Nyeong Lee Dae Won Jun Chang Soo Eun Oh Young Lee Yong Chul Jeon Dong Soo Han Byung Chul Yoon Ho Soon Choi Joon Soo Hahm Seung Sam Paik | 2011 | Gastrointestinal Endoscopy2011，，3： | 1 |
| 4 | Treatment of Epstein-Barr virus–associated gastric carcinoma with endoscopic submucosal dissection显示文摘 | Hang Lak Lee Dong Chan Kim Sang Pyo Lee Kang Nyeong Lee Dae Won Jun Oh Young Lee Dong Soo Han Byung Chul Yoon Ho Soon Choi Joon Soo Hahm Ki-Seok Jang | 2012 | Gastrointestinal Endoscopy2012，，4： | 1 |
| 5 | Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis显示文摘BACKGROUND Fexuprazan,a novel potassium-competitive acid blocker,reversibly suppresses the K+/H+-ATPase enzyme in proton pumps within gastric parietal cells.Fexuprazan’s suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent manner.AIM To compare fexuprazan to esomeprazole and establish its efficacy and safety in patients with erosive esophagitis(EE).METHODS Korean adult patients with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg or esomeprazole 40 mg once daily for eight weeks.The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy at week 8.The secondary endpoints included the healing rate of EE at week 4,symptom response,and quality of life assessment.Safety profiles and serum gastrin levels were compared between the groups.RESULTS Of the 263 randomized,218 completed the study per protocol(fexuprazan 40 mg,n=107;esomeprazole 40 mg,n=111).Fexuprazan was non-inferior to esomeprazole regarding the healing rate at week 8[99.1%(106/107)vs 99.1%(110/111)].There were no between-group differences in the EE healing rate at week 4[90.3%(93/103)vs 88.5%(92/104)],symptom responses,and quality of life assessments.Additionally,serum gastrin levels at weeks 4 and 8 and drug-related side effects did not significantly differ between the groups.CONCLUSION Fexuprazan 40 mg is non-inferior to esomeprazole 40 mg in EE healing at week 8.We suggest that fexuprazan is an alternative promising treatment option to PPIs for patients with EE. | Kang Nyeong Lee Oh Young Lee Hoon Jai Chun Jin Il Kim Sung Kook Kim Sang Woo Lee Kyung Sik Park Kook Lae Lee Suck Chei Choi Jae-Young Jang Gwang Ha Kim In-kyung Sung Moo In Park Joong Goo Kwon Nayoung Kim Jae Jun Kim Soo Teik Lee Hyun Soo Kim Ki Bae Kim Yong Chan Lee Myung-Gyu Choi Joon Seong Lee Hwoon-Yong Jung Kwang Jae Lee Jie-Hyun Kim Hyunsoo Chung | 2022 | World Journal of Gastroenterology2022，28，44： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员